Folic Acid
| Evidence Level: L4 | Predicted Indications: 1 |
Table of Contents
Using the given Evidence Pack directly (no fabrication beyond documented fields); original indication/MOA fields are genuine data gaps in the pack, so they’re flagged rather than guessed.
Folic Acid: From Vitamin B9 Supplementation to Biotin Metabolic Disease
One-Sentence Summary
Folic acid (DrugBank DB00158) is a water-soluble B-vitamin conventionally used to treat and prevent folate deficiency. The TxGNN model predicts a possible role in biotin metabolic disease (e.g., biotinidase deficiency), but this is currently supported only by 13 indirect clinical trials (none testing folic acid specifically for this condition) and 20 publications, all reviews or cohort studies — no RCTs.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not specified in evidence pack (folic acid is generally classified as a vitamin/nutrient supplement) |
| Predicted New Indication | Biotin metabolic disease |
| TxGNN Prediction Score | 99.49% |
| Evidence Level | L4 |
| India Market Status | ✗ Not Marketed (Not marketed) |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available for folic acid in this evidence pack. Based on known pharmacology, folic acid (vitamin B9) functions in one-carbon metabolism and nucleic acid synthesis, while biotin (vitamin B7) acts as a cofactor for carboxylase enzymes — these are distinct metabolic pathways with no direct enzymatic overlap.
Biotin metabolic diseases (such as biotinidase deficiency or holocarboxylase synthetase deficiency) are standardly treated with biotin supplementation itself, not folic acid. The two compounds share only a superficial classification as “water-soluble B-vitamins.”
The model’s high score (99.49%) most likely reflects a knowledge-graph clustering effect — vitamin-class drugs and vitamin-responsive metabolic disorders tend to co-occur as connected node groups — rather than a specific, validated biological mechanism. This interpretation is reinforced by the evidence itself: among the retrieved clinical trials, none directly test folic acid for biotin metabolic disease, and the literature consists exclusively of reviews discussing B-vitamins generically (several explicitly grouping folate and biotin together as “vitamin-responsive disorders” without establishing a folic acid–specific therapeutic link).
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT05687474 | N/A | Completed | 6,824 | Universal newborn genomic screening program (Baby Detect) covering 126 treatable genetic diseases, potentially including biotin-related disorders; not a folic acid intervention study |
| NCT01474486 | N/A | Completed | 40 | Feasibility of multi-micronutrient palliative intervention in congestive heart failure |
| NCT04312152 | N/A | Unknown | 200 | Cross-over RCT of Q10 ubiquinol + multivitamin B/E complex in idiopathic and Phelan-McDermid syndrome autism |
| NCT03444155 | N/A | Completed | 30 | Pilot comparing natural vs. synthetic vitamin B-complex (includes folic acid and biotin) bioavailability |
| NCT07350538 | N/A | Active, not recruiting | 20 | Exploratory gut microbiome profiling and personalized prebiotic intervention for alcohol addiction recovery |
| NCT01173315 | Phase 2 | Completed | 75 | Vitamin/mineral supplementation effect on neuropathy and nephropathy in type 2 diabetes |
| NCT04586348 | Phase 4 | Active, not recruiting | 794 | Prenatal iodine supplementation and early childhood neurodevelopment |
| NCT03360435 | N/A | Completed | 99 | Transdermal vitamin absorption in post-bariatric surgery patients |
| NCT00572741 | N/A | Completed | 39 | Targeted nutritional intervention for oxidative stress and metabolic pathology in autism |
| NCT01558193 | N/A | Completed | 202 | Multivitamin/mineral ± omega-3 fatty acid supplementation and impulsivity/aggression |
None of the above trials directly evaluate folic acid monotherapy for biotin metabolic disease; all involve multi-nutrient formulations or unrelated indications.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 38203763 | 2024 | Review | Int J Mol Sci | Discusses vitamin B12 as cofactor alongside biotin and folic acid in methionine/succinyl-CoA synthesis; no direct folic acid–biotin disease link established |
| 30557456 | 2019 | Review | Mov Disord | Reviews movement disorders in treatable inborn errors of metabolism, including vitamin-responsive conditions |
| 23622402 | 2013 | Review | Handb Clin Neurol | Reviews vitamin-responsive disorders of cobalamin, folate, biotin, B1 and E; groups folate and biotin deficiencies as distinct clinical entities |
| 37123774 | 2023 | Review | Cureus | Relationship between vitamins (including biotin) and type 2 diabetes |
| 25388747 | 2015 | Review | Endocr Metab Immune Disord Drug Targets | Vitamins (including biotin, pyridoxine) and type 2 diabetes mellitus |
| 41692080 | 2026 | Review | Clin Dermatol | Overview of B-vitamin roles in dermatology, including biotin |
| 29173522 | 2017 | Review | Gastroenterol Clin North Am | Vitamin and mineral deficiencies (including folate) in inflammatory bowel disease |
| 7027768 | 1981 | Review | Acta Vitaminol Enzymol | Reviews vitamin involvement in metabolic diseases via malabsorption, metabolic errors, and vitamin-dependent syndromes |
| 1368195 | 1992 | Review | J Chem Technol Biotechnol | Biotechnological production of vitamins and coenzymes, including biotin |
| 36197290 | 2022 | Cohort | Microbiol Spectr | Gut microbiota and metabolomic changes (including B-vitamin metabolism) in seafarers after long voyages |
No RCT evidence exists linking folic acid to biotin metabolic disease; all retrieved literature is review-level and largely discusses B-vitamins as a class.
India Market Information
Folic acid currently holds no marketing authorization record in this dataset (market status: Not marketed / Not Marketed; 0 registrations). No license or product information is available.
Safety Considerations
- Drug Interactions: 430 documented interactions recorded (DDInter). Most entries have no graded severity (“Unknown”); notable graded interactions include Pancrelipase (Moderate) and Sulfasalazine (Minor).
- TFDA label warnings and contraindications have not yet been retrieved (source: TFDA official site, blocking gap) — required before any formal safety evaluation (S1 stage) can proceed.
Conclusion and Next Steps
Decision: Hold
Rationale: The predicted association rests on a single high TxGNN score with no supporting mechanistic data (MOA unavailable) and no direct clinical or literature evidence — all retrieved trials and publications address B-vitamins generically rather than folic acid specifically for biotin metabolic disease, and the two compounds act through unrelated metabolic pathways. Evidence level is L4 (mechanism/preclinical-level at best), and the drug is not currently marketed, further limiting near-term actionability.
To proceed, the following is needed:
- TFDA label warnings/contraindications (blocking gap, DG001)
- Verified mechanism of action data (DG002)
- A dedicated study isolating folic acid’s effect in biotin-responsive metabolic disorders (current evidence is confounded by multi-vitamin co-administration)
- Clarification of current regulatory/market status before any registration pathway is considered
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.